News

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
The last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...
Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from ...
U.S. Defense Secretary Pete Hegseth announced Tuesday that a Confederate memorial would be reinstalled in Arlington Cemetery ...
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...
Vinay Prasad, a top regulator at the US Food and Drug Administration, ended his short tenure at the agency after conservative ...
I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...